Sign In
Last checked at 
3 Feb 2011 10:21
Notification of major interests in shares
LONDON, 3 February 2011 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (DIFX: HIK), the fast growing multinational pharmaceuticals group, announces as follows:
1 | Identity of the issuer or the underlying issuer of existing shares to which the voting rights are attached | Hikma Pharmaceuticals PLC
|
2 | Reason for the notification | |
An acquisition or disposal of voting rights | Yes | |
An acquisition or disposal of financial instruments which may result in the acquisition of shares already issues to which voting rights are attached | No | |
An event changing the breakdown of voting rights | No | |
Other (please specify): Compliance with the Transparency Directive | No |
3 | Full name of the person subject to the notification obligation | Sectoral Asset Management Inc. (SAM) | ||||||||
4 | Full name of shareholders | SAM acts as investment advisors/sub investment advisors to a large number of institutional clients globally. The actual shareholders are those institutional clients, some of whom have delegated voting authority to SAM. | ||||||||
5 | Date of the Transaction (and date on which the threshold crossed is reached differently) | 1 February 2011 | ||||||||
6 | Date on which the issuer notified | 2 February 2011 | ||||||||
7 | Threshold that is crossed | 3% | ||||||||
8 | Notified details: | |||||||||
A. Voting rights attached to shares | ||||||||||
Class type of shares (if possible using the ISIN code) | Situation previous to the triggering transaction | Resulting situation after the triggering transaction | ||||||||
Number of shares | Number of voting rights | Number of shares | Number of voting rights | % of voting rights | ||||||
Direct | Indirect | Direct | Indirect | Direct | Indirect | |||||
Ordinary Shares (0.10 GBP) GB00B0LCW083 | 5,592,174 | 2,587,193 with SAM 3,004,981 with clients | 6,222,574 | 0 | 2,677,293 with SAM 3,545,281 with clients | 0 | 1.38% with SAM 1.83% with clients | 0% | ||
B. Qualifying Financial instruments | ||||
Resulting situation after the triggering transaction | ||||
Type of financial instrument | Expiration Date | Exercise/Conversion Period/Date | Number of voting rights that may be acquired if the instrument if exercised/converted | % of voting rights |
- | - | - | - | - |
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments | ||||||
Resulting situation after the triggering transaction | ||||||
Type of financial instrument | Exercise Price | Expiration Date | Exercise/Conversion Period/Date | Number of voting rights instrument refers to | % of voting rights | |
Nominal | Delta | |||||
- | - | - | - | - | - | - |
Total A+B+C | |
Number of Voting rights | % of voting rights |
SAM: 2,677,293 Clients: 3,545,281 | SAM: 1.38% Clients: 1.83% |
9 | Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable | |
|
Proxy Voting | ||
10 | Name of the proxy holder | Sectoral Asset Management Inc (SAM) in respect of 1.38% of Hikma shares |
11 | Number of voting rights proxy holder will cease to hold | N/A |
12 | Date on which proxy holder will cease to hold voting rights | N/A |
13 | Additional Information | Notification using the total voting rights figure of 193,516,989
|
14 | Contact name: | Peter Speirs, Deputy Secretary |
15 | Contact telephone number: | 020 7399 2772 |
- ENDS -
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2009, Hikma achieved revenues of $637 million and profit attributable to shareholders of $78 million. For news and other information, please visit www.hikma.com.
Follow the stocks
